The symptoms associated with benign prostatic hyperplasia (BPH) such as urinary frequency, nocturia, weak stream, hesitancy and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to the prostate size. But prostate size alone does not correlate with symptom severity. The dynamic component is a function of the smooth muscle tone in the prostate and its capsule, the bladder neck and the bladder base as well as the prostatic urethra.
The smooth muscle tone is regulated by alpha-adrenergic receptors. Alfuzosin is an orally active quinazoline derivative, peripherally acting antagonist, exhibits selectivity for postsynaptic alpha-1 adrenergic receptors in the lower urinary tract. Blockade of these adrenoceptors can cause smooth muscle in the bladder neck and prostate to relax, resulting in an improvement in urine flow and a reduction in symptoms of BPH.
Benign prostatic hyperplasia: The recommended dose is 10 mg to be taken once daily after a meal.
Acute Urinary Retention: In patients 65 years and older, 10 mg daily after a meal to be taken from the first day of catheterisation. The treatment should be administered for 3-4 days, 2-3 days during catheterisation and 1 day after its removal. In this indication no benefit has been established in patients under 65 years of age or if treatment is extended beyond 4 days.